Drug Profile
Research programme: radiolabelled anticancer antibodies - Probactive Biotech
Alternative Names: Biopharmaceuticals for cancer - Probactive Biotech/Dalat Nuclear Research Institute; Iodine 131-labelled anticancer antibodies - Probactive Biotech/Dalat Nuclear Research Institute; Yttrium 90-labelled anticancer antibodies - Probactive Biotech/Dalat Nuclear Research InstituteLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Probactive Biotech
- Developer Dalat Nuclear Research Institute; Probactive Biotech
- Class Antibodies; Radiopharmaceuticals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Vietnam (Parenteral)
- 24 Jun 2010 Preclinical trials in Cancer in USA (Parenteral)